Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 185
- Registration Number
- NCT05180006
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT05132582
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Other, Spain
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 927
- Registration Number
- NCT05113251
- Locations
- 🇹🇭
Research Site, Khon Kaen, Thailand
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 53
- Registration Number
- NCT05041842
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Institut fuer Frauengesundheit
- Target Recruit Count
- 108
- Registration Number
- NCT05036005
- Locations
- 🇩🇪
Department of Gynecology and Obstetrics, Dresden University Hospital Carl-Gustav Carus, Dresden, Saxony, Germany
🇩🇪Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Bottrop, North Rhine-Westphalia, Germany
🇩🇪Department for Hematology, Oncology and Tumor Immunology Charité Campus Benjamin Franklin, Berlin, Germany
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 185
- Registration Number
- NCT05020860
- Locations
- 🇺🇸
Harris Health System - Smith Clinic, Houston, Texas, United States
🇺🇸O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- AC Camargo Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04993014
- Locations
- 🇧🇷
A.C. Camargo Cancer Center, São Paulo, Brazil
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 214
- Registration Number
- NCT04957212
- Locations
- 🇮🇷
Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
🇮🇷Amir Hospital, Shiraz, Iran, Islamic Republic of
🇮🇷Shahid Faghihi Hospital, Shiraz, Iran, Islamic Republic of
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1157
- Registration Number
- NCT04784715
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.